Condensed Consolidated Statements of Cash Flows	3 Months Ended	9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Cash flows from operating activities:
Net loss		$ (10,843,502)	$ (110,219,885)
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development			72,523,293
Depreciation and amortization		2,066	6,788
Stockbased compensation		361,598	16,923,911
Amortization of right of use lease asset			182,042
Foreign currency gain	$ 2,880	(39,686)	(315,130)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		1,077,138	3,166,506
Accounts payable		21,873	(565,203)
Accrued expenses and other liabilities		982,563	(2,510,258)
Lease liability			(182,688)
Net cash used in operating activities		(8,437,950)	(20,990,624)
Cash flows from investing activities:
Purchases of property and equipment		(85,943)
Net cash used in investing activities		(85,943)
Cash flows from financing activities:
Proceeds from issuance of common stock		5,788,918	584,447
Common stock issuance costs		(648,928)
Net cash provided by financing activities		5,139,990	584,447
Change in cash and cash equivalents and restricted cash		(3,383,903)	(20,406,177)
Effect of exchange rate changes on cash		(8,782)	442,726
Cash, cash equivalents and restricted cash-beginning of year		28,786,647	53,076,052
Cash, cash equivalents and restricted cash-end of period	25,393,962	25,393,962	33,112,601
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	25,353,513	25,353,513	33,112,601
Restricted cash	40,449	40,449
Total cash, cash equivalents and restricted cash	$ 25,393,962	$ 25,393,962	33,112,601
Non-cash investing and financing activities:
Operating lease liabilities arising from obtaining right-of-use assets			113,612
Issuance of convertible preferred stock and common stock in connection with acquisition			$ 70,107,167